When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
OTIC - Otonomy begins mid-stage trial of OTO-313 in tinnitus
Otonomy Inc.
Otonomy (NASDAQ:OTIC) has initiated a Phase 1/2 clinical trial of OTO-313, a sustained-exposure formulation of the NMDA receptor antagonist gacyclidine, in patients with tinnitus.
More news on: Otonomy, Inc., Healthcare stocks news,